Targets › AR
66 programs from 60 companies in 247 trials: 138 Phase 2, 61 Phase 3, 33 Phase 1, 15 Phase 4; Oncology, Metabolic and endocrine, Genitourinary; next expected readout Nov 2026.
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling…. (UniProt, P10275)
Open in Phaseline: the race on AR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ottawa Hospital Research Institute | ARPI (androgen receptor pathway inhibitor) Androgen receptor pathway inhibitor | AR | Phase 4 | Metastatic Breast Cancer | Mar 2027 |
| Bayer | Darolutamide Androgen Receptor antagonist | AR | Phase 4 | Non-metastatic Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Cancer; Cancer; High-risk Localized Prostate Cancer … | Jul 2027 |
| Bradley Nindl | Testosterone Androgen Receptor agonist | AR | Phase 4 | Musculoskeletal Injury | Aug 2027 |
| Alexandra Kautzky-Willer | Testosterone Androgen Receptor agonist | AR | Phase 4 | Fatty Liver | Sep 2028 |
| Lise Aksglæde | Testosterone Androgen Receptor agonist | AR | Phase 4 | Klinefelter Syndrome | Dec 2029 |
| Sun Pharmaceutical Industries | Clascoterone Androgen Receptor antagonist | AR | Phase 4 | Acne Vulgaris | – |
| Tolmar | Testosterone Undecanoate Androgen Receptor agonist | AR | Phase 4 | Hypogonadism; Prostate Cancer | – |
| Johnson & Johnson (Janssen) | Apalutamide Androgen Receptor antagonist | AR | Phase 3 | Prostatic Neoplasms; Metastatic Castrate-sensitive Prostate Cancer | Dec 2026 |
| Université de Sherbrooke | Androgen blockade (18 months) + radiation therapy LHRH agonist with initial total androgen blockade for 18 months combined with pelvic and p | AR | Phase 3 | Prostate Cancer | Dec 2026 |
| Aragon Pharmaceuticals | Apalutamide (ARN-509) Androgen Receptor antagonist | AR | Phase 3 | Prostatic Neoplasms; Prostate Cancer; Prostatic Neoplasms, Castration-Resistant; Androgen Axis Suppression … | Mar 2027 |
| Jiangsu HengRui Medicine | Rezvilutamide Androgen Receptor antagonist | AR | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer (Post Prostatectomy) … | Mar 2027 |
| Amneal Pharmaceuticals | Testosterone Cypionate Androgen Receptor agonist | AR | Phase 3 | Male Hypogonadism; Weaning Failure; Transgenderism; Localized Prostate Carcinoma … | Mar 2027 |
| Khyber Medical University Peshawar | Danazol Progesterone receptor agonist; Androgen Receptor agonist | PGR, AR | Phase 3 | Beta-Thalassemia | Apr 2027 |
| University of Sao Paulo General Hospital | Testosterone Androgen Receptor agonist | AR | Phase 3 | Menopause | Apr 2027 |
| Pfizer | Enzalutamide Androgen Receptor antagonist | AR | Phase 3 | Hormone Sensitive Prostate Cancer | Jul 2027 |
| Merck & Co. (MSD) | Opevesostat (MK-5684) 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor blocking steroid hormone synt | HSD11B1, AR | Phase 3 | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer Metastatic; Malignant Neoplasm; Prostatic Neoplasms, Castration-Resistant … | Nov 2027 |
| Canisius-Wilhelmina Hospital | Testosterone Androgen Receptor agonist | AR | Phase 3 | Prostatic Neoplasms | Dec 2027 |
| Halozyme Therapeutics | Testosterone Enanthate Androgen Receptor agonist | AR | Phase 3 | Hypogonadism, Male; Spinal Cord Injury; Prostate Cancer; Castration Resistant Metastatic Prostate Cancer … | Mar 2028 |
| Novartis | Enzalutamide Androgen Receptor antagonist | AR | Phase 3 | Prostate Cancer; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms; Castration-Resistant Prostate Carcinoma … | Sep 2028 |
| Sir Mortimer B. Davis - Jewish General Hospital | Testosterone Androgen Receptor agonist | AR | Phase 3 | Prostate Cancer | Dec 2028 |
| Astellas | Enzalutamide Androgen Receptor antagonist | AR | Phase 3 | Metastatic Hormone Sensitive Prostate Cancer | Dec 2028 |
| Assistance Publique - Hôpitaux de Paris | Testosterone Androgen Receptor agonist | AR | Phase 3 | Gender Dysphoria | Jun 2029 |
| Radiation Therapy Oncology Group | Anti-androgen Androgen receptor antagonist | AR | Phase 3 | Prostate Cancer | Jul 2031 |
| Canadian Cancer Trials Group | Testosterone Androgen Receptor agonist | AR | Phase 3 | Prostate Cancer | Oct 2032 |
| Sun Yat-sen University | Testosterone Androgen Receptor agonist | AR | Phase 3 | Prostate Cancer (Post Prostatectomy) | Dec 2033 |
| European Organisation for Research and Treatment of Cancer - EORTC | iMAB (intermittent maximum androgen blockade) Intermittent LHRH agonist/antagonist + ARPI (abiraterone, enzalutamide, apalutamide, or da | AR | Phase 3 | Prostate Cancer | May 2035 |
| Zhejiang Sunshine Mandi Pharmaceutical | Clascoterone Androgen Receptor antagonist | AR | Phase 3 | Acne Vulgaris; Papular-pustular Rosacea; Pilonidal Disease | – |
| Seattle Institute for Biomedical and Clinical Research | Testosterone Androgen Receptor agonist | AR | Phase 2 | Hypogonadism, Male | Nov 2026 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Abiraterone Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor | CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3 | Phase 2 | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma … | Nov 2026 |
| Martin T. King, MD, PhD | Androgen Deprivation Therapy (ADT) Lowering testosterone levels to slow or shrink prostate tumors; may include injectable or | AR | Phase 2 | Intermediate Risk Prostate Cancer | Dec 2026 |
| University of Wisconsin, Madison | pTVG-AR DNA vaccine encoding androgen receptor ligand-binding domain | AR | Phase 2 | Castration-resistant Prostate Cancer; Prostate Cancer | Dec 2026 |
| Fudan University | SHR 3680 Androgen receptor antagonist | AR | Phase 2 | Advanced Salivary Gland Carcinoma | Dec 2026 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Darotamide Androgen receptor antagonist | AR | Phase 2 | Neoadjuvant Therapy | Dec 2026 |
| University Hospital, Ghent | Testosterone Androgen Receptor agonist | AR | Phase 2 | Prostate Cancer | Dec 2026 |
| University of Maryland, Baltimore | galeterone Androgen Receptor antagonist; Cytochrome P450 17A1 inhibitor | AR, CYP17A1 | Phase 2 | Advanced Pancreatic Cancer | Dec 2026 |
| University Hospital, Clermont-Ferrand | Testosterone Androgen Receptor agonist | AR | Phase 2 | Critical Illness | Apr 2027 |
| Science Valley Research Institute | Oxandrolone Androgen Receptor agonist | AR | Phase 2 | Anterior Cruciate Ligament (ACL) Reconstruction | Apr 2027 |
| University of Southern California | Danazol Progesterone receptor agonist; Androgen Receptor agonist | PGR, AR | Phase 2 | Cirrhosis, Liver | Aug 2027 |
| VA Office of Research and Development | Testosterone Androgen Receptor agonist | AR | Phase 2 | Metastatic Prostate Cancer | Aug 2027 |
| Veru | Enobosarm Androgen Receptor modulator | AR | Phase 2 | Obesity & Overweight | Oct 2027 |
| University Hospital, Strasbourg, France | Testosterone Androgen Receptor agonist | AR | Phase 2 | Multiple Sclerosis, Relapsing-Remitting | Dec 2027 |
| Sun Pharmaceutical Industries | Enzalutamide Androgen Receptor antagonist | AR | Phase 2 | Metastatic Cancer | Dec 2027 |
| University of Virginia | Testosterone Androgen Receptor agonist | AR | Phase 2 | Prostate Cancer | Jan 2028 |
| Roche | Enzalutamide Androgen Receptor antagonist | AR | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Mar 2028 |
| St. Louis University | Testosterone Androgen Receptor agonist | AR | Phase 2 | Hypogonadism, Male | Jun 2028 |
| University of Washington | Testosterone Androgen Receptor agonist | AR | Phase 2 | Castration-Resistant Prostate Carcinoma | Sep 2028 |
| QuantumLeap Healthcare Collaborative | Testosterone Androgen Receptor agonist | AR | Phase 2 | Ductal Carcinoma in Situ | Nov 2028 |
| Case Comprehensive Cancer Center | Testosterone Androgen Receptor agonist | AR | Phase 2 | Prostate Cancer | Dec 2028 |
| University of Chicago | Testosterone Androgen Receptor agonist | AR | Phase 2 | Prostate Cancer | Dec 2028 |
| VA Office of Research and Development | Flutamide Androgen Receptor antagonist | AR | Phase 2 | Prostate Cancer | Mar 2029 |
| Astellas | enzalutamide Androgen Receptor antagonist | AR | Phase 2 | Prostate Cancer | Jul 2029 |
| Memorial Sloan Kettering Cancer Center | BMS986365 (CC-94676) Androgen receptor (AR) ligand-directed degrader | AR | Phase 2 | Prostate Cancer | Jan 2030 |
| City of Hope Medical Center | ADT (Androgen Deprivation Therapy) Androgen receptor pathway inhibition through hormone depletion | AR | Phase 2 | Prostate Cancer | May 2030 |
| University of Texas Southwestern Medical Center | Testosterone Androgen Receptor agonist | AR | Phase 2 | Prostate Cancer | Nov 2030 |
| Affidea Nu-med Center of Oncological DIagnostics and Therapy | Testosterone Androgen Receptor agonist | AR | Phase 2 | Prostate Cancer; Prostate Cancer (Adenocarcinoma) | Dec 2033 |
| AstraZeneca | AZD9750 AR-PROTAC (proteolysis-targeting chimera) | AR | Phase 1 | Prostate Cancer | Nov 2026 |
| Qilu Pharmaceutical | QLH12016 Androgen receptor PROTAC | AR | Phase 1 | Advanced Prostate Cancer | Dec 2026 |
| Johnson & Johnson (Janssen) | JNJ-86974680 ARv7 inhibitor | AR | Phase 1 | Prostatic Neoplasms | Jan 2027 |
| Alessa Therapeutics | Bicalutamide Androgen Receptor antagonist | AR | Phase 1 | Prostate Adenocarcinoma; Androgen Deprivation Therapy; Prostate Cancer; Castration Levels of Testosterone … | Apr 2027 |
| Novartis | ARV-766 Androgen receptor antagonist | AR | Phase 1 | Prostate Cancer Metastatic | May 2027 |
| University of California, Los Angeles | Testosterone Androgen Receptor agonist | AR | Phase 1 | Hypogonadism, Male | Jun 2027 |
| Weill Medical College of Cornell University | Testosterone Androgen Receptor agonist | AR | Phase 1 | Prostate Cancer | Oct 2027 |
| Hansoh BioMedical R&D Company | HRS-5041 Androgen receptor PROTAC degrader | AR | Phase 1 | Advanced Prostate Cancer | Dec 2027 |
| St Vincent's Hospital, Sydney | Seviteronel Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist | CYP17A1, AR | Phase 1 | Triple Negative Breast Cancer | Dec 2027 |
| Ellipses Pharma | EP0062 Selective androgen receptor modulator (SARM) | AR | Phase 1 | Hormone Receptor-positive Breast Cancer | Feb 2028 |
| Alessa Therapeutics | Enzalutamide Androgen Receptor antagonist | AR | Phase 1 | Prostate Adenocarcinoma | Dec 2028 |
Prostate Cancer (74) Prostatic Neoplasms (11) Prostate Adenocarcinoma (9) Metastatic Castration-resistant Prostate Cancer (8) Metastatic Prostate Cancer (7) Castration-Resistant Prostate Carcinoma (7) Hypogonadism, Male (5) Prostatic Neoplasms, Castration-Resistant (4) Prostate Cancer Metastatic Disease (4) Prostate Cancer Metastatic (3) Prostate Cancer (Adenocarcinoma) (3) Neoadjuvant Therapy (3)
small molecule (58), mixed (5), antibody (1)
Johnson & Johnson (Janssen) (2) Novartis (2) Astellas (2) VA Office of Research and Development (2) Alessa Therapeutics (2) Sun Pharmaceutical Industries (2) Martin T. King, MD, PhD (1) Hansoh BioMedical R&D Company (1) Merck & Co. (MSD) (1) University of California, Los Angeles (1) QuantumLeap Healthcare Collaborative (1) Bayer (1) Qilu Pharmaceutical (1) Lise Aksglæde (1) University Hospital, Strasbourg, France (1) Canisius-Wilhelmina Hospital (1) Aragon Pharmaceuticals (1) Alexandra Kautzky-Willer (1) Weill Medical College of Cornell University (1) Affidea Nu-med Center of Oncological DIagnostics and Therapy (1)
CYP17A1 (3) PGR (2) HSD11B1 (1) SRD5A1 (1) SRD5A2 (1) SRD5A3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.